FutureFuel (FF) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
10 Nov, 2025Executive summary
Revenue declined 56% year-over-year to $22.7 million for Q3 2025 and 58% to $75.9 million for the nine months ended September 30, 2025, driven by weak biofuel market conditions and plant idling.
Net loss widened to $9.3 million for Q3 2025 and $37.4 million for the nine months, compared to net income of $1.2 million and $12.7 million in the prior-year periods.
Adjusted EBITDA was negative $6.8 million for Q3 and negative $32.7 million for the nine months, reflecting operational challenges and lower sales.
Strategic initiatives led to sequentially reduced net losses over the past three quarters.
Financial highlights
Gross loss was $6.8 million for Q3 2025 and $30.2 million for the nine months, compared to gross profit of $0.4 million and $14.0 million in the prior-year periods.
Operating expenses decreased $0.4 million in Q3 but increased $1.1 million for the nine months, mainly due to higher compensation and R&D costs.
Cash used in operating activities was $1.3 million for the nine months, compared to $41.4 million provided in the prior year.
Cash and cash equivalents stood at $85.6 million as of September 30, 2025, down from $109.5 million at year-end 2024.
Capital expenditures for nine months 2025 were $14.8 million, up from $10.6 million in 2024.
Outlook and guidance
Management expects continued uncertainty in the renewable fuel market due to pending EPA rules and evolving tax credit structures.
Expecting to restart biodiesel production in late Q4 2025 as input costs decrease and regulatory clarity improves.
Anticipate new chemical production ramping up in 2026 and debottlenecking projects coming online over the next few quarters.
The company retains capacity to restart biodiesel production when market conditions improve.
Latest events from FutureFuel
- Annual meeting to elect directors, approve pay, and ratify auditor, with board size reduced.FF
Proxy filing - Q2 2026 saw revenue surge 121% and a return to profitability, driven by robust Chemicals and Biofuels growth.FF
Q2 2026 - Revenue up 82% year-over-year, but net loss widened on derivative and storm impacts.FF
Q1 2026 - 2025 saw steep losses and revenue declines, but new plant investments and regulatory clarity support a 2026 rebound.FF
Q4 2025 - Annual meeting to elect directors, ratify auditor, and update governance and compensation.FF
Proxy Filing - Shareholders will elect directors, ratify a new auditor, and see board and leadership changes.FF
Proxy Filing - Q2 2025 revenue fell 51% and net loss reached $10.4M as biodiesel production was idled.FF
Q2 2025 - Q3 loss and cash decline driven by biofuel weakness, margin pressure, and special dividend.FF
Q3 2024 - Q2 net income reached $9.6M as margins improved despite lower revenue and market pressures.FF
Q2 2024